A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Exclusion Criteria

• •Subject has a substance dependence disorder that has not been in sustained remission for at least 1 year;
• •Diagnosis of schizoaffective disorder;
• •Bipolar disorder, manic episode, dementia, OCD, or drug-induced psychosis or current major depressive disorder;
• •Diagnoses with mental retardation; acute psychosis hospitalization within past 6 months;
• •Current clozapine treatment; suicidal ideation or behavior;
• •BMI of 39 or greater; current homicidal or violent ideation;
• •Medical or CNS condition other than schizophrenia that could affect cognitive performance or testing; relevant drug sensitivity or allergy; positive urine screen for alcohol or drugs of abuse;
• •Positive hepatitis or HIV test result;
• •Recent clinically significant illness/infection or surgery;
• •Recent blood product transfusion, donation or loss of 5 mL/kg of blood;
• •Visual, hearing or communication disability